David Brian Shackelford, PhD

David Brian Shackelford, PhD

University of California, Los Angeles

Research Project:
Testing Novel Compound to Treat KRAS/LKB1 Mutant Lung Tumors

Grant Awarded:

  • Lung Cancer Discovery Award

Research Topics:

  • biomarkers
  • immunology immunotherapy

Research Disease:

  • lung cancer

Non-small cell lung cancer (NSCLC) claimed the lives of an estimated 135,000 in the U.S. in 2021. Despite recent breakthroughs in targeted and immunotherapy, most patients with advanced NSCLC develop therapy-resistant disease, leading to a 5-year survival rate of approximately 6%. Subsets of lung tumors with mutations in the KRAS and LKB1 genes have proven to be highly resistant to immune-based therapeutic approaches. Patients with KRAS/LKB1 mutant lung tumors represent a large lung cancer population for whom effective therapies are greatly needed. As such, there is a critical need to identify novel therapeutic and diagnostic approaches to treat this deadly disease. We have discovered a novel compound that selectively kills KRAS/LKB1 mutant lung tumors that we will test in this study. This drug represents an effective and novel class of compound that we aim to develop for the treatment of therapy resistant KRAS/LKB1 mutant lung cancer. 

Page last updated: January 26, 2023

Freedom From Smoking Clinic
Online, CA | Jan 03, 2023
Freedom From Smoking Clini
Berkeley, CA | Jan 25, 2023